Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

NCT01421524 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

271

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Lymphoma, Large B-Cell, Diffuse
Pleiotropic Pathway Modifier
Glioblastoma
Lymphoma
Primary Central Nervous System Lymphoma

Interventions

DRUG: CC-122
DRUG: CC-122
DRUG: CC-122
DRUG: CC-122

Sponsor

Celgene